Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
HELIUM, USP is an inhaled gas product approved by the FDA in 2013 for use as a respiratory therapeutic agent. It is administered via inhalation and operates as a medical gas without a defined pharmacologic mechanism of action. The product is currently in peak lifecycle stage.
Product is at peak commercial maturity with moderate competitive pressure (30%), suggesting stable but non-growth team dynamics.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Advanced Solutions Life Sciences is hiring 1 role related to this product
Only 2 linked job opportunities exist for HELIUM, USP, concentrated in IT and early-career/internship tracks, indicating a small team footprint. This product offers limited senior career advancement opportunities but may suit early-stage professionals seeking foundational pharma experience.
2 open roles linked to this drug